Rentschler Appoints New Chief Business Officer
News Mar 08, 2013
Rentschler Biotechnologie GmbH has announced the appointment of Frank Ternes to the position of Chief Business Officer effective February 1, 2013.
In this position, Mr. Ternes will contribute to the success of the organization by leading the planning, development and execution of all business development, sales & marketing and project management activities.
"Mr. Ternes is an excellent addition to Rentschler's management board," says Dr. Nikolaus F. Rentschler, CEO and owner of Rentschler.
Dr. Rentschler continued, "With his broad experience in the contract manufacturing business, he has a keen understanding of technology, a strong customer focus, and a proven track record for achieving success.”
Frank Ternes brings more than 25 years of experience from Operations and Technology at Boehringer Ingelheim where he last served as Senior Vice President of Biopharmaceutical Contract Manufacturing.
Mr. Ternes holds a degree equivalent to a master’s degree in economics from the University of Bonn, Germany.
Uptake of Controlled Release Drug Delivery Technology Set to Increase?News
The increasing access to healthcare facilities and the bolstering need for drugs to be used orally has been driving the consumption of generic drugs among people across the world, which, in turn, is fueling the need for controlled release technology for drug delivery to suffice the availability of drugs in small dosages.READ MORE
SYGNIS AG Signs Supply Agreement with US Biological for the Lightning-Link Antibody Labelling TechnologyNews
SYGNIS AG, the Group which includes Expedeon Holdings, Innova Biosciences, and C.B.S. Scientific Company, announced it has signed a supply agreement with US Biological, Salem, MA, USA, for its Innova Lightning-Link® technology.READ MORE